Literature DB >> 3124974

Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation.

H K Gold1, B S Coller, T Yasuda, T Saito, J T Fallon, J L Guerrero, R C Leinbach, A A Ziskind, D Collen.   

Abstract

The effects of bolus injections of recombinant single-chain tissue-type plasminogen activator (rt-PA) and of F(ab')2 fragments of a murine monoclonal antibody (7E3) against the human platelet GPIIb/IIIa receptor [7E3-F(ab')2] on coronary arterial thrombolysis and reocclusion was studied in a canine preparation of coronary artery thrombosis superimposed on high-grade stenosis. Bolus intravenous injections of rt-PA at a dose of 0.45 mg/kg, repeated at 15 min intervals until reperfusion occurred (maximum of four injections) caused reperfusion in five of seven dogs within 100 min (33 +/- 15 min, mean +/- SD). Reperfusion was rapidly followed (generally within 10 min) by reocclusion and then by periods of cyclical reflow and reocclusion. A single intravenous injection of 7E3-F(ab')2 alone at 0.8 mg/kg caused reperfusion within 100 min in two of six dogs (19 and 37 min) without subsequent reocclusion. Single bolus injections of different amounts (0.1 to 0.8 mg/kg) of 7E3-F(ab')2 were then combined with bolus injections of 0.45 mg/kg of rt-PA. Stable reperfusion without reocclusion was accomplished with 0.8 or 0.6 mg/kg 7E3-F(ab')2 and a single injection of 0.45 mg/kg rt-PA within 6 +/- 3 min (n = 6, p less than .01) and 8 +/- 5 min (n = 5, p less than .02), respectively. None of these animals suffered reocclusion of the coronary artery. Lower doses (0.1 to 0.2 mg/kg) of 7E3-F(ab')2 did not significantly shorten the time to reperfusion and did not prevent reocclusion.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3124974     DOI: 10.1161/01.cir.77.3.670

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  51 in total

1.  Improving reperfusion after myocardial infarction.

Authors:  I B Menown; A A Adgey
Journal:  BMJ       Date:  1999-12-11

Review 2.  Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction.

Authors:  M P Hudson; A B Greenbaum; R A Harrington; E M Ohman
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

Review 3.  Assessing the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention. Rationale and design of the GOLD study.

Authors:  S R Steinhubl
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

4.  Augmentation of in-vitro clot dissolution by low frequency high-intensity ultrasound combined with antiplatelet and antithrombotic drugs.

Authors:  S Atar; H Luo; Y Birnbaum; T Nagai; R J Siegel
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

Review 5.  Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.

Authors:  G Proimos
Journal:  J Thromb Thrombolysis       Date:  2001-04       Impact factor: 2.300

Review 6.  Platelet activation in acute myocardial infarction and the rationale for combination therapy.

Authors:  I Conde-Pozzi; N Kleiman
Journal:  Curr Cardiol Rep       Date:  2000-09       Impact factor: 2.931

7.  Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials.

Authors:  Ulf Bertram; Martin Moser; Karlheinz Peter; Helmut F Kuecherer; Raffi Bekeredjian; Andreas Straub; Thomas K Nordt; Christoph Bode; Johannes Ruef
Journal:  J Thromb Thrombolysis       Date:  2002-12       Impact factor: 2.300

Review 8.  Advances in thrombolytic therapy.

Authors:  M Verstraete
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

9.  Current status of thrombolytic therapy in acute myocardial infarction.

Authors:  B Stein; R Roberts
Journal:  Tex Heart Inst J       Date:  1991

10.  Correlation between clinical course and quantitative analysis of the ischemia related artery in patients with unstable angina pectoris, refractory to medical treatment. Results of two randomized trials. The European Cooperative Study Group.

Authors:  M J van den Brand; A van Miltenburg; M J de Boer; L R van der Wieken; P J de Feyter; M L Simoons
Journal:  Int J Card Imaging       Date:  1994-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.